# Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
Canonical URL: https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-inclusion-in-the-russell-2000-index-expanding-ma-949bcb8c
Ticker: DTIL
Company: Precision BioSciences
Source: Precision BioSciences
Published: 2026-06-29 11:01 EST
Original Source URL: https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-inclusion-russell-2000r-index
## Summary

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 29, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000

## Article Body
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 29, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000
## Recent Company News
- 2026-06-29 11:01 EST — [Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors](https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-inclusion-in-the-russell-2000-index-expanding-ma-949bcb8c) — Source: Precision BioSciences
- 2026-06-25 13:46 EST — [Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026](https://biopharmsignal.com/news/DTIL/precision-biosciences-announces-new-and-late-breaking-pbgene-hbv-clinical-data-from-the-eliminate-b-study-at-european-association-for-the-study-of-the-liver-congress-2026) — Source: Precision BioSciences
- 2026-06-25 13:46 EST — [Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026](https://biopharmsignal.com/news/DTIL/precision-biosciences-to-host-investor-webcast-to-discuss-late-breaking-pbgene-hbv-data-from-eliminate-b-trial-presented-at-european-association-for-the-study-of-the-liver-congress-2026) — Source: Precision BioSciences
- 2026-06-25 13:46 EST — [Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting](https://biopharmsignal.com/news/DTIL/precision-biosciences-presents-new-preclinical-data-supporting-the-advancement-of-pbgene-dmd-into-clinic-at-the-american-society-of-gene-and-cell-therapy-2026-annual-meeting) — Source: Precision BioSciences
- 2026-06-25 13:46 EST — [Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program](https://biopharmsignal.com/news/DTIL/precision-biosciences-receives-u-s-patent-allowances-covering-the-pbgene-hbv-program) — Source: Precision BioSciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)